Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination

1. Yale University School of Medicine, New Haven, CT, USA; 2. Barts Heart Centre, London and Queen Mary University of London, London, United Kingdom; 3. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, and Saolta University Healthcare Group, University College Hospital Galway, Galway, Ireland; 4. Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy; 5. Center for Devices and Radiological Health, Food and Drug Administration, Gaithersburg, MD, USA; 6. Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 7. Fu Wai Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences, National Clinical Research Centre for Cardiovascular Diseases, Beijing, China; 8. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University, Homburg (Saar), Germany; 9. Institute for Medical Engineering and Science, MIT, Cambridge, MA, USA